Li Ran, Zhang Ye, Liu Qian, Gao Aiqin, Dang Qi
Shandong Second Medical University, Weifang, China.
Department of Thoracic Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, Shandong First Medical University, Jinan, China.
Medicine (Baltimore). 2024 Dec 27;103(52):e38881. doi: 10.1097/MD.0000000000038881.
Nuclear protein in testis carcinoma (NC) is a rare, aggressive, poorly differentiated squamous cell carcinoma. By reviewing the entire treatment process of the patient, we aim to explore the treatment experience of NC.
We report the case of a 27-year-old female patient with NC whose initial symptoms were occasional cough and chest tightness with abdominal distension for more than half a month without any other specific discomfort.
Computed tomography showed right lung hilar and right middle and lower lobe mass, malignant, right hilar and mediastinal lymph node metastasis, and bilateral cystic solid masses in the adnexal region, malignant possibility. Pathological diagnosis showed nuclear protein in the testis (+).
After the failure of first-line chemotherapy with immunocombination, second-line chemotherapy was switched to bevacizumab, which resulted in a progression-free survival of 6 months.
The disease then reprogressed, and she died on November 7, 2022.
The patient achieved survival of nearly 1 year on multiple courses of therapy, well beyond the currently reported median survival. The patient achieved a 6-month progression-free survival, suggesting that combination therapy with antivascular endothelial growth factor class-targeted agents is a potential approach.
睾丸癌核蛋白（NC）是一种罕见的、侵袭性的、低分化鳞状细胞癌。通过回顾该患者的整个治疗过程，我们旨在探索NC的治疗经验。
我们报告了一名27岁患有NC的女性患者的病例，其最初症状为偶尔咳嗽、胸闷伴腹胀超过半个月，无任何其他特殊不适。
计算机断层扫描显示右肺门及右中下叶肿块，为恶性，右肺门及纵隔淋巴结转移，附件区双侧囊实性肿块，有恶性可能。病理诊断显示睾丸核蛋白（+）。
一线免疫联合化疗失败后，二线化疗改用贝伐单抗，无进展生存期为6个月。
随后疾病复发进展，她于2022年11月7日死亡。
该患者通过多疗程治疗实现了近1年的生存，远超目前报道的中位生存期。该患者实现了6个月的无进展生存期，提示抗血管内皮生长因子类靶向药物联合治疗是一种潜在的治疗方法。
